Oxycodone

cytochrome P450 family 2 subfamily D member 6 ; Homo sapiens







62 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34480108 Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests. 2022 Feb 4
2 35201310 Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors. 2022 Feb 1 1
3 33085221 Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States. 2021 Jan 1
4 33387367 Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. 2021 Oct 1
5 33799050 Oxycodone findings and CYP2D6 function in postmortem cases. 2021 Jul 2
6 34267337 Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). 2021 Jul 15 2
7 34565798 Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). 2021 Sep 27 1
8 34575542 Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism. 2021 Sep 14 5
9 34581987 Sex and Estrous Cycle Differences in Analgesia and Brain Oxycodone Levels. 2021 Dec 4
10 34922356 Urinary Pharmacokinetics of Immediate and Controlled Release Oxycodone and its Phase I and II Metabolites using LC-MS/MS. 2021 Dec 18 1
11 31925778 Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions. 2020 Feb 3
12 29714124 Clinical application of pharmacogenetics in pain management. 2018 Mar 1
13 29801577 Pharmacogenetics in Pain Treatment. 2018 1
14 30425549 CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort. 2018 2
15 27692933 Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP-glucuronosyltransferases. 2017 Sep 10 1
16 28244808 CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. 2017 Mar 4
17 28340451 The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. 2017 Apr 1
18 28769582 CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications. 2017 1
19 27388970 The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. 2016 Nov 1
20 27702939 Degradation of Opioids and Opiates During Acid Hydrolysis Leads to Reduced Recovery Compared to Enzymatic Hydrolysis. 2016 Oct 1
21 24975450 CYP2D6-inhibiting drugs and the increased risk of fall-related injuries due to newly initiated opioid treatment--a Swedish, register-based case-crossover study. 2015 Feb 2
22 25948306 [Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients]. 2015 1
23 26447442 Pharmacogenetics: Using Genetic Information to Guide Drug Therapy. 2015 Oct 1 1
24 24495562 The CYP2D6 gene determines oxycodone's phenotype-specific addictive potential: implications for addiction prevention and treatment. 2014 Mar 5
25 24517173 Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. 2014 May 4
26 24523296 Observations of urinary oxycodone and metabolite distributions in pain patients. 2014 Apr 1
27 25121773 Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. 2014 1
28 25518025 Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model. 2014 Dec 17 1
29 23555934 CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. 2013 4
30 23588782 Applications of CYP450 testing in the clinical setting. 2013 Jun 1
31 23605691 Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications. 2013 May 2
32 23783165 Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers. 2013 Aug 1
33 21735164 Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. 2012 Jan 2
34 22148986 Is maternal opioid use hazardous to breast-fed infants? 2012 Jan 1
35 22452458 Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation. 2012 Jul 2
36 22694279 Preventing opioid-related deaths in children undergoing surgery. 2012 Jul 1
37 22747548 Non-analgesic effects of opioids: interactions between opioids and other drugs. 2012 1
38 23226064 Pharmacogenomic considerations in opioid analgesia. 2012 4
39 20857093 Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. 2011 Jan 2
40 21173180 Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. 2011 Mar 1
41 21174486 Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. 2011 Jan 1 1
42 21209234 CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. 2011 Nov 2
43 19719813 Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. 2010 Feb 3
44 19755414 Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. 2010 Jan 1
45 20504256 Personalized therapy in pain management: where do we stand? 2010 Jun 1
46 20590587 The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. 2010 Jun 4
47 20590588 Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. 2010 Jun 6
48 20642550 Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. 2010 Jul 12
49 29913934 Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients. 2010 Jan 1 3
50 19281600 The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. 2009 Apr 2